The CARE Chest X-Ray (CXR) Triage software reportedly bolsters consistent flagging of suspicious chest X-rays for lung collapse and pneumomediastinum across reviewing readers of different experience levels.
|Articles|January 12, 2015
Very Low-Dose Chest CT Protocols 3rd gen recon Software
Very Low-Dose (0.15 mGy) Chest CT Protocols Using the COPDGene 2 Test Object and a Third-Generation Dual-Source CT Scanner With Corresponding Third-Generation Iterative Reconstruction Software.
Related to this article
In a study involving over 700 participants who had chest CT and brain MRI, those with diabetes and lower vertebral bone mineral density (vBMD) had a nearly five percent faster total accumulation of white matter hyperintensity (WMH) in comparison to those without diabetes.
Indicated for the treatment of foregut, midgut and hindgut neuroendocrine tumors, the radiopharmaceutical Bravnetsa is reportedly bioequivalent and therapeutically equivalent to the previously FDA-approved Lutathera.
Newly cleared findings for the adjunctive AI platform a2z-Abdo-Triage include acute appendicitis, renal traumatic injury, ureteral stone and retroperitoneal hematoma.
In multivariable external testing, tumor structure habitat phenotypes from pre-treatment MRI revealed more than a doubling of recurrence risk for women with stage 2 and stage 3 breast cancer.
Could a la carte pricing be a consideration in improving revenue for radiologists in private practice?
Catch up on a variety of FDA news in radiology from the past week.
Catch up on the top radiology content of the past week.
Trending on Diagnostic Imaging
1
Study Links AI BMD Assessment on Chest CT to Faster Cognitive Decline and White Matter Changes on Brain MRI
2
FDA Clears AI-Powered Triage Software for 10 Findings on Abdominopelvic CT
3
FDA Grants Final Approval of Emerging Radiopharmaceutical for GEP-NET Treatment
4
Can MRI-Derived Tumor Habitat Subregions Bolster Recurrence Risk Stratification in Stage 2 and 3 Breast Cancer Cases?
5